Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery
NCT00977457 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1045
Last updated 2025-08-19
Summary
This trial studies the side effects and best way to perform genetic testing in predicting biomarkers of recurrence in patients with prostate cancer undergoing surgery. Collecting and storing samples of tissue, blood, and other body fluids from patients to test in the laboratory and collecting information about the patient's health and treatment may help doctors learn more about cancer and help predict the recurrence of prostate cancer
Conditions
Interventions
- GENETIC
-
DNA analysis
Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
- GENETIC
-
DNA methylation analysis
Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
- GENETIC
-
RNA analysis
Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
- GENETIC
-
gene expression analysis
Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
- GENETIC
-
polymerase chain reaction
Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
- OTHER
-
diagnostic laboratory biomarker analysis
Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
- PROCEDURE
-
therapeutic conventional surgery
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
City of Hope Medical Center
lead OTHER
Principal Investigators
-
Steven S. Smith, PhD · City of Hope Medical Center
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-11-26
- Primary Completion
- 2016-07-13
- Completion
- 2026-07-08
Countries
- United States
Study Locations
More Related Trials
-
Molecular Mechanisms Underlying Prostate Cancer Disparities
NCT02229565 ·Status: COMPLETED
-
An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males
NCT00342771 ·Status: COMPLETED
-
Prostate Cancer Prospective Cohort
NCT00937586 ·Status: ACTIVE_NOT_RECRUITING
-
Surgery in Treating Patients With Prostate Cancer
NCT00002938 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15
NCT00955435 ·Status: UNKNOWN
-
Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting
NCT03912883 ·Status: ACTIVE_NOT_RECRUITING
-
Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
NCT02458716 ·Status: COMPLETED ·Phase: PHASE1
-
Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study
NCT00342433 ·Status: COMPLETED
-
Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study
NCT04254133 ·Status: ENROLLING_BY_INVITATION
-
Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY
NCT02269982 ·Status: COMPLETED
-
PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802
NCT01672905 ·Status: COMPLETED
-
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
NCT03934606 ·Status: COMPLETED
-
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
NCT01953640 ·Status: ACTIVE_NOT_RECRUITING
-
Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer
NCT01325311 ·Status: COMPLETED ·Phase: PHASE2
-
Study of How People Make Decisions About Prostate Cancer Risk
NCT07197723 ·Status: RECRUITING
-
Precision Medicine in the Prostate Cancer Care Pathway
NCT04763317 ·Status: RECRUITING
-
Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse
NCT00071968 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate Cancer
NCT00959023 ·Status: UNKNOWN
-
Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program
NCT00035217 ·Status: COMPLETED
-
Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer
NCT02440802 ·Status: UNKNOWN
-
S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin
NCT01120262 ·Status: COMPLETED
-
Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803
NCT00897351 ·Status: COMPLETED
-
Early Stage Prostate Cancer Cohort
NCT00011349 ·Status: COMPLETED
-
Prostate Cancer - Comparative Outcomes of New Conceptual Paradigms for Treatment
NCT04890314 ·Status: COMPLETED
-
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3